IU Home Pages - Logo   May 28, 2004  
 
Home Events FYI Headliners Health Liberal 
arts Outreach Technology Research Contact  
Conversations Viewpoint Fast facts Web mastery @ 
Work Photographer's corner Friday flashback
  Health
Dad’s Day 5K June 14 to benefit prostate cancer research
By Joe Stuteville



Ninety percent of prostate cancers diagnosed in the early stages are survivable.
Dad’s Day 5K June 14 to benefit prostate cancer research

By Joe Stuteville

Many fathers know best when it comes to prostate cancer and understanding its risks—and they’ll be taking that message to the streets in Indiana’s state capital Father’s Day weekend.

The “Dad’s Day 5K” run-and-fitness walk will step off 8 a.m., Saturday, June 14. The event and registration area is at the IU Cancer Center Pavilion, 535 Barnhill Drive, Indianapolis, on the campus of IUPUI.

Proceeds from the event will benefit cancer research at IUSM and the Little Red Door, a support agency for medically underserved cancer patients sponsored by the Central Indiana Prostate Cancer Foundation, Inc.

“Prostate cancer remains the leading killer cancer among men, but early detection and treatment can lead to complete recovery,” said Dr. Michael Koch.

“If prostate cancer is caught early, survival rates are 90 percent or higher,” he said. “However, there often are no early warning signs or symptoms of the disease and the only way to detect prostate cancer in its early stages is through a prostate specific antigen blood test and a digital rectal exam.”

PSA is a protein produced in the cells in the prostate gland. When the prostate gland enlarges, PSA levels in the blood tend to rise and might indicate cancer or benign conditions.

As pink ribbons have become symbolic to breast cancer awareness, a sky-blue ribbon is the emblem worn by prostate cancer survivors, their families, scientists and other advocates. Participants and supporters of the “Dad’s Day 5K” will wear their ribbons on the day of the event.

http://www.indydadsday5k.org

Related stories:
Second race in July to focus on prostate cancer among black men
At 76, Roeske is the ‘father of Plenaxis’
Roeske receives Innovator of Year Award